Eliezer M. Van Allen

Dana-Farber Cancer Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

111h-index79.5kcitations1.4kworks4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(366), Cancer Immunotherapy and Biomarkers(325), Bladder and Urothelial Cancer Treatments(193), Prostate Cancer Treatment and Research(188), Renal cell carcinoma treatment(146)

Publications1.4k total

Abstract PR001: Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer
Cancer Research·2026
Conserved Neuronal-like and Secretory Programs Define the Spatial Architecture of Gastroenteropancreatic Neuroendocrine Tumors
2025Open Access
Learning Patient Similarity from Genomics for Precision Oncology
2025Open Access
Mechanisms of tumor persistence in metastatic melanoma following successful immunotherapy
2025Open Access
Evaluation of single-cell RNA profiling technologies using FFPE, fresh, and frozen ccRCC tumor specimens
2025Open Access
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer
Nature Communications·2025· 2 citedOpen Access
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
Nature Communications·2025· 1 citedOpen Access
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2025Open Access
Supplementary Vignette 3 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
2025Open Access
Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Supplementary Vignette 2 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
2025Open Access
Table S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S10 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Supplementary Vignette 1 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology
2025Open Access
Figure S7 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
page 1 of 72Next →

Frequent Co-authors

Levi A. Garraway(24), Gad Getz(23), Michael S. Lawrence(13), Stacey Gabriel(11), Diana Miao(10), Philip W. Kantoff(9), Jaegil Kim(9), Mara Rosenberg(9), Toni K. Choueiri(9), Nikhil Wagle(9), Nikolaus Schultz(8), Scott L. Carter(8), Himisha Beltran(7), Andrea Sboner(7), Mark A. Rubin(7), Matthew Meyerson(7), Dirk Schadendorf(7), Kristian Cibulskis(7), Francesca Demichelis(6), Peter S. Nelson(6)